comparemela.com

Latest Breaking News On - Pathology intelligence - Page 1 : comparemela.com

CellCarta stärkt sein Geschäft mit histologischen Biomarkern durch die Akquisition des auf künstlicher Intelligenz basierenden Marktführers für quantitative Pathologie Reveal Biosciences

Montreal (ots/PRNewswire) - CellCarta, ein globaler Anbieter von Dienstleistungen im Bereich der Präzisionsmedizin, gab heute die Übernahme von Reveal Biosciences ("Reveal") bekannt, einem in San Diego

CellCarta Strengthens its Histological Biomarker Franchise by [ ] | Comunicati stampa CataniaOggi

11 maggio 2021 14:35 Fonte: Adnkronos #chimica-e-farmacia - MONTREAL, May 11, 2021 /PRNewswire/ CellCarta, a global provider of precision medicine services, announced today the acquisition of Reveal Biosciences ( Reveal ), a San Diego California based computational pathology company offering cutting-edge artificial intelligence (AI)-based quantitative pathology and immunohistochemistry services to the biopharmaceutical industry. This acquisition further strengthens CellCarta s position as a leading provider of histopathology biomarker services and will enable the company to broaden its offering in AI-enabled multi-omic data analysis services and applications. Reveal Biosciences has created a new generation of Pathology Intelligence™ to enhance research, clinical trials, and improve patient outcomes globally.  Reveal s imageDx™ pathology platform combines cutting edge machine learning (ML)-AI with traditional histopathology to transform tissue biology into actionable data.

CellCarta Strengthens its Histological Biomarker Franchise by Acquiring Artificial Intelligence-Based Quantitative Pathology Leader Reveal Biosciences

Reveal Biosciences Logo (CNW Group/CellCarta) MONTREAL, May 11, 2021 /PRNewswire/ - CellCarta, a global provider of precision medicine services, announced today the acquisition of Reveal Biosciences ( Reveal ), a San Diego California based computational pathology company offering cutting-edge artificial intelligence (AI)-based quantitative pathology and immunohistochemistry services to the biopharmaceutical industry. This acquisition further strengthens CellCarta s position as a leading provider of histopathology biomarker services and will enable the company to broaden its offering in AI-enabled multi-omic data analysis services and applications. Reveal Biosciences has created a new generation of Pathology Intelligence™ to enhance research, clinical trials, and improve patient outcomes globally.  Reveal s imageDx™ pathology platform combines cutting edge machine learning (ML)-AI with traditional histopathology to transform tissue biology into actionable data.  Reveal s uniq

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.